Stress Management for Patients With Multiple Sclerosis
Phase II Study of the Effects of Stress Management on Neuroimaging, Clinical, Immune and Psychosocial Outcomes
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94121
- UCSF Behavioral Medicine Research Center
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University, Department of Preventive Medicine
-
-
Washington
-
Kirkland, Washington, United States, 98034
- MS Center at Evergreen Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Confirmed diagnosis of MS
- New Gd+ MRI brain lesion or clinically diagnosed exacerbation within the previous 12 months.
- Able to speak english.
- Age 18 or over.
- Able to give informed consent.
- Patients taking the drug glatiramer acetate must have been on the drug for at least 6 months prior to their Gd+ MRI brain lesion and/or exacerbation.
- Patients taking an interferon beta drug must have been on the drug for at least 1 month prior to their Gd+ MRI brain lesion and/or exacerbation.
- Patients not on disease modifying treatment are not planning to initiate treatment.
Exclusion Criteria:
- Meets criteria for dementia by scoring below the 5th percentile in 3 or more of 6 areas of neuropsychological functioning or as determined by study neuropsychologist.
- Severe psychiatric pathology, including schizophrenia, bipolar disorder, current alcoholism or substance abuse, or other severe psychiatric disorder for which this intervention would be inappropriate.
- Active and severe suicidal ideation.
- Endocrine or metabolic disorder.
- Currently in psychotherapy.
- Initiated antidepressant therapy within the past 4 weeks.
- Received corticosteroid treatment within the past 28 days.
- Pregnant or planning pregnancy in the next 12 months.
- Has any non-removable metal or medical device in the body for which an MRI could pose a danger.
- Has any risk factors for developing nephrogenic systemic fibrosis (NSF) or is allergic to Gadolinium.
- Currently uses a Baclofen pump.
- Has an Expanded Disability Status Scale score greater than 6.5.
- Recently begun relaxation, meditation, yoga, or similar form of disease management course within the past 3 months.
- Treatment with Chemotherapy.
- Treatment with Tysabri.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Individual Stress Management
Stress management therapy for multiple sclerosis (SMT-MS) is a manualized, validated, published stress management program designed for patients with MS.
Participants met with a therapist for 16 individual 50-minute sessions conducted over 20-24 weeks.
The first 6 sessions focused on teaching problem solving skills, relaxation, increasing positive activities, cognitive restructuring, and enhancement of social support.
Participants were able to tailor the treatment to meet their needs using optional treatment modules including communication and assertiveness training, fatigue management, anxiety reduction, pain management, management of cognitive problems, insomnia treatment, and management of sexual dysfunction.
|
Stress management therapy for multiple sclerosis (SMT-MS) is a manualized, validated, published stress management program designed for patients with MS.
Participants met with a therapist for 16 individual 50-minute sessions conducted over 20-24 weeks.
The first 6 sessions focused on teaching problem solving skills, relaxation, increasing positive activities, cognitive restructuring, and enhancement of social support.
Participants were able to tailor the treatment to meet their needs using optional treatment modules including communication and assertiveness training, fatigue management, anxiety reduction, pain management, management of cognitive problems, insomnia treatment, and management of sexual dysfunction.
Other Names:
|
|
Other: Wait List Control
Wait List Control provided treatment as usual for the first 10+ months of participation.
A 5-hour workshop was provided after the 10th month.
This allowed at least 2 post-treatment MRI evaluation that were not contaminated by the workshop.
|
Wait List Control provided treatment as usual for the first 10+ months of participation.
A 5-hour workshop was provided after the 10th month.
This allowed at least 2 post-treatment MRI evaluation that were not contaminated by the workshop.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
No.of Gd+ Lesions From Week 8 to Week 24
Time Frame: week 8 to week 24
|
Gd+ is Gadolinium-enhancing MRI brain lesion, A marker of the opening of the blood-brain barrier and is typically used as a primary endpoints in phase II trials because of its high sensitivity to ongoing MS disease activity and its association with clinical exacerbation.
The single value was calculated by summing up the lesions from week 8 to week 24.
|
week 8 to week 24
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
No.of New or Enlarged T2 Lesions From Week 8 to Week 24
Time Frame: week 8 to week 24
|
T2-weighted MRI is commonly used in phase II trials to identify more permanent lesions.
The single value was calculated by summing up the lesions from week 8 to week 24.
|
week 8 to week 24
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: David C. Mohr, Ph.D., Northwestern University
- Study Director: Joyce Ho, PhD, Northwestern University
- Principal Investigator: David Daikh, MD, University of California, San Francisco
Publications and helpful links
General Publications
- Mohr DC, Lovera J, Brown T, Cohen B, Neylan T, Henry R, Siddique J, Jin L, Daikh D, Pelletier D. A randomized trial of stress management for the prevention of new brain lesions in MS. Neurology. 2012 Jul 31;79(5):412-9. doi: 10.1212/WNL.0b013e3182616ff9. Epub 2012 Jul 11.
- Burns MN, Nawacki E, Kwasny MJ, Pelletier D, Mohr DC. Do positive or negative stressful events predict the development of new brain lesions in people with multiple sclerosis? Psychol Med. 2014 Jan;44(2):349-59. doi: 10.1017/S0033291713000755. Epub 2013 May 17.
- Burns MN, Nawacki E, Siddique J, Pelletier D, Mohr DC. Prospective examination of anxiety and depression before and during confirmed and pseudoexacerbations in patients with multiple sclerosis. Psychosom Med. 2013 Jan;75(1):76-82. doi: 10.1097/PSY.0b013e3182757b2b. Epub 2012 Nov 28.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SIMS
- R01HD043323 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.